Fas-Fas ligand system in the peripheral blood of patients with renal diseases

Nephron

Volumn 85, Issue 2, 2000, Pages 107-113

  Sato, Masashi ^a   Konuma, Takako ^a   Yanagisawa, Naoki ^a   Haizuka, Hisatoshi ^a   Asakura, Hiroshi ^a   Nakashima, Yutaka ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Fas Fas ligand system; Mononuclear cells; Renal disease

Indexed keywords

FAS LIGAND;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; KIDNEY DISEASE; MONONUCLEAR CELL; NICK END LABELING; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEINURIA;

EID: 0034076738     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000045642     Document Type: Article

References (25)

1. Baker AJ, Mooney A, Hughes J, Lombardi D, Johnson RJ, Savill J: Mesangial cell apoptosis: The major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. J Clin Invest 1994;94: 2105-2116.
2. Shimizu A, Kitamura H, Masuda Y, Ishizaki M, Sugisaki Y, Yamanaka N: Apoptosis in the repair process of experimental proliferative glomerulonephritis. Kidney Int 1995;47:114-121.
3. Sugiyama H, Kashihara N, Makino H, Yamasaki Y, Ota Z: Apoptosis in glomerular sclerosis. Kidney Int 1996;49:103-111.
4. Bonventre JV: Mechanisms of ischemic acute renal failure. Kidney Int 1993;43:1160-1178.
5. Woo D: Apoptosis and loss of renal tissue in polycystic kidney diseases. N Engl J Med 1995; 333:18-25.
6. Yonehara S, Ishii A, Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989;169: 1747-1756.
7. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer M, Kiefer MC, Barr PJ: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-1762.
8. Suda T, Takahashi T, Goldstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-1178.
9. Kayagaki N, Kayagaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H: Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995;182:1777-1783.
10. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Nashhimoto H: Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 1997;40: 1126-1129.
11. Sano H, Asano K, Minatoguchi S, Hiraka J, Fujisawa K, Nishigaki K, Yasuda N, Kumada H, Takumura M, Ohashi H, Seishima M, Fuziwara T, Fujiwara H: Plasma soluble Fas and soluble Fas ligand in chronic glomerulonephritis. Nephron 1998;80:153-161.
12. Aringer M, Wintersberger W, Steiner CW, Kiener H, Prtesterl E, Jaeger U, Smolen JS, Graninger WB: High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes, of patients with systemic lupus erythematosus. Arthritis Rheum 1994;37:1423-1430.
13. Sato M, Kino K, Nabeshima K, Koshikawa S: Antilymphocyte antibodies against CD4+CD45R+ subsets in patients with IgA nephropathy. Nephron 1992;60:397-403.
14. Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Anderson M, Kerwar SS, Torrance DS, Otten-Evans C, Greenstreet T, Weerawarna K: Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994;370:218-220.
15. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S: Fas ligand in human serum. Nat Med 1996; 2:317-322.
16. Kayagiya N, Yamaguchi N, Nagao F, Matsuo S, Maeda H, Okumura K, Yagita H: Polymorphism of murine Fas ligand that affects the biological activity. Proc Natl Acad Sci USA 1997; 94:3914-3919.
17. Reed JC, Miyashita T, Cuddy M, Cho D: Regulation of p26-Bcl-2 protein levels in human peripheral blood lymphocytes. Lab Invest 1992;67:443-449.
18. Tokano Y, Miyake S, Kayagaki N, Nozawa K, Morimoto S, Azuma M, Yagita H, Takasaki Y, Okumura K, Hashimoto H: Soluble Fas molecule in the serum of patients with systemic lupus erythematosus. J Clin Immunol 1996;16: 261-265.
19. Tashiro K, Kodera S, Takahashi Y, Horikoshi S, Shirato T, Tomino Y: Detection of apoptotic cells in glomeruli of patients with IgA nephropathy. Nephron 1998;79:21-27.
20. Ohsako S, Hara M, Harigai M, Fukasawa C, Kashiwazaki S: Expression and function of Fas antigen and bcl-2 in human systemic lupus erythematosus lymphocytes. Clin Immunol Immunopathol 1994;73:109-114.
21. Emlen W, Niebur J, Kadera R: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994;152:3685-3692.
22. Sato M, Konuma T, Haizuka H, Asakura H, Nakashima Y: Expression of Fas antigen on CD4 subsets in peripheral blood from patients with IgA nephropathy. Nephron 1999;81:349-350.
23. Vaishnaw AK, McNalley JD, Elkon KB: Apoptosis in the rheumatic disease. Arthritis Rheum 1997;40:1919-1927.
24. Wardle EN: Cytokine growth factors and glomerulonephritis. Nephron 1991;57:257-261.
25. Goel N, Ulrich DT, Clair EW, Fleming JA, Lynch DH, Seldin MF: Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum 1995; 38:1738-1743.